Solstice® Propellant delivers significant performance, safety and environmental benefits
Honeywell (NYSE: HON) announced today that its low-global-warming propellant, Solstice® Propellant, is being used in a new diaper rash aerosol treatment for infants, toddlers and adults.
Mission Pharmacal Co., a U.S. manufacturer of diaper rash ointments, is using Solstice Propellant in its new line of Dr. Smith's®-brand diaper rash sprays. Solstice Propellant, which has a global warming potential (GWP) of less than 1, enables the new product line to have a lower global warming impact than aerosols using other propellants. The new products are some of the first low-GWP spray treatments for rashes on the market today.
"Solstice Propellant provides Mission Pharmacal and its customers with the best of both worlds - the performance of today's propellants with greatly reduced environmental impact," said David Cooper, global business director for Honeywell's Fluorine Products business. "Because it complies with major environmental regulations around the world, Solstice Propellant is being steadily adopted by companies seeking to sell their products in multiple markets."
In addition to personal care products, Solstice Propellant is used in aerosols for automotive, electronics and industrial applications, including air horns, dusters and cleaning sprays. Honeywell announced in July 2011 that it was investing $33 million in its Baton Rouge, La. manufacturing facility to supply Solstice Propellant to aerosol manufacturers globally.
"When we were looking at propellants to use in our new aerosol diaper rash sprays, it became clear that Solstice Propellant satisfied our product performance needs," said Neill Walsdorf Jr., president of Mission Pharmacal Co. "It provides significant environmental benefits, meets all of our formulation requirements, and easily integrates into our manufacturing process."
Solstice Propellant offers an excellent safety and environmental profile in personal care applications, including diaper sprays. It has a GWP of less than 1, is nonflammable per ASTM E681 and ISO 10156:2010 testing, and is non-ozone depleting. It is considered a replacement for HFC-134a propellant, which has a GWP of 1,300. It is also not a volatile organic compound (VOC), as determined by the U.S. Environmental Protection Agency (EPA).
Mission Pharmacal Co. is a privately-held pharmaceutical company based in San Antonio, Texas, that has been committed to meeting the unique healthcare needs of women, pediatric patients and those dealing with urologic and dermatologic conditions for more than 65 years.
In addition to Solstice Propellant, Honeywell's family of Solstice-branded products includes stationary and mobile refrigerants, liquid and gaseous blowing agents, and solvents based on Honeywell's new hydrofluoro-olefin technology that helps customers lower their carbon footprint without sacrificing end-product performance. These products have been developed and are being commercialized by Honeywell's Fluorine Products business, a leader in the manufacture and supply of non-ozone-depleting refrigerants used by top air-conditioning and refrigeration makers worldwide, blowing agents for energy-efficient foam insulation, and environmentally-preferable solvents.
www.honeywell-solstice-propellants.com
